New research out of VCU Massey Cancer Center suggests that the inactivation of NF1—a gene known as Neurofibromin-1 that holds natural tumor-suppressing functions—could be instrumental in the onset of pancreatic cancer, either in tandem with KRAS mutations, which occur in 85-90% of all pancreatic tumors, or even before any mutations occur in the KRAS gene, in partnership with TP53, the most inactivated tumor suppressor gene in human malignancies.
Researchers at VCU Massey Cancer Center published study findings that establish rationale for the use of a class of drugs known as MDA-9 inhibitors as a potential treatment option for aggressive liver cancer.Â
Researchers at VCU Massey Cancer Center identified a novel, protein-based combination therapy through which tumor resistance can be overcome to more effectively treat colorectal cancer.Â
Virginia Commonwealth University Health System opened the Adult Outpatient Pavilion, which is now the system’s largest outpatient facility.
